Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

489
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
489
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

481
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
481
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

418
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
418
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

517
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
517
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

318
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
318
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

353
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
353

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of guideline adherence to hypertension-mediated organ damage screening in Korean patients with hypertension: results from the Korean Registry of Target Organ Damage in Hypertension (KorHR).

Clinical hypertension·2026
Same author

Residual congestion at discharge assessed by bioelectrical impedance and its prognostic value in acute heart failure: a multi-centre, prospective registry study.

ESC heart failure·2026
Same author

High-Sensitivity Cardiac Troponin as a Predictor of Atrial Fibrillation Detected After Stroke: Implications for Subsequent Cerebrocardiovascular Events.

Journal of clinical medicine·2025
Same author

Sex and Age Differences in the Impact of Metabolic Syndrome on Heart Failure Development.

Metabolites·2024
Same author

ROsulord® sAfety for Patients with Dyslipidemia Study: A Non-interventional, Multicenter, Prospective, Observational Study in South Korea.

Cardiology and therapy·2024
Same author

The Impact of Metabolic Syndrome on Heart Failure in Young Korean Population: A Nationwide Study.

Metabolites·2024

Related Experiment Video

Updated: Jan 20, 2026

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

13.9K

Tachycardia induced Cardiomyopathy.

Do Young Kim1, Sung Hea Kim2, Kyu Hyung Ryu3

  • 1Cardiovascular Center, Korea University Anam Hospital, Seoul, Korea.

Korean Circulation Journal
|August 29, 2019
PubMed
Summary

Tachycardia-induced cardiomyopathy (T-CMP) is a reversible heart dysfunction. Early recognition and treatment of the underlying arrhythmia can restore left ventricular function, highlighting the need for more clinical research.

Keywords:
CardiomyopathiesHeart failureTachycardia

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.3K
A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

21.9K

Related Experiment Videos

Last Updated: Jan 20, 2026

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

13.9K
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.3K
A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

21.9K

Area of Science:

  • Cardiology
  • Electrophysiology
  • Heart Failure Research

Background:

  • Radiofrequency catheter ablation (RFCA) is effective for atrial fibrillation in heart failure (HF) patients.
  • Tachycardia-induced cardiomyopathy (T-CMP) is increasingly recognized as a significant clinical concern.
  • T-CMP involves reversible left ventricular (LV) dysfunction caused by tachyarrhythmias.

Purpose of the Study:

  • To highlight the growing importance of tachycardia-induced cardiomyopathy.
  • To emphasize the need for early T-CMP recognition and treatment.
  • To underscore the limited clinical data available for human T-CMP.

Main Methods:

  • Review of recent studies on RFCA and its impact on HF patients.
  • Analysis of the relationship between tachyarrhythmias and LV dysfunction.
  • Discussion of therapeutic options for T-CMP.

Main Results:

  • T-CMP is a potentially reversible cause of LV dysfunction.
  • Prompt treatment of the causative tachyarrhythmia can lead to LV function recovery.
  • T-CMP can be a primary condition or a contributing factor in HF patients.

Conclusions:

  • Early identification and management of T-CMP are crucial for improving LV function.
  • Catheter ablation is a viable therapeutic option for T-CMP.
  • Further clinical research is essential due to the increasing prevalence of T-CMP.